葛兰素史克Glaxosmithkline plc (GSK) 2010年年度报告「LSE」.pdf

1、GlaxoSmithKline Annual Report 2010Do more,feel better,live longerGSK Annual Report 2010Business review2010 Performance overview 08Research and development 10Pipeline summary 12Products,competition and intellectual property 14Regulation 18Manufacturing and supply 19World market 20GSK sales performanc

2、e 21Segment reviews 22Responsible business 29Financial review 2010 34Financial position and resources 41Financial review 2009 47Risk factors 53Governance and remunerationOur Board 58Our Corporate Executive Team 60Governance and policy 64Dialogue with shareholders 69Internal control framework 71Commi

3、ttee reports 74Remuneration policy 84Director terms and conditions 91Director and Senior Management remuneration 94Directors interests 96Directors interests in contracts 101Financial statementsDirectors statement of responsibilities 102Independent Auditors report 103Financial statements 104Notes to

4、the financial statements 109Financial statements of GlaxoSmithKline plc prepared under UK GAAP 188Shareholder informationQuarterly trend 192Five year record 200 Product development pipeline 203Share price and dividends 207Nature of trading market 208Annual General Meeting 208Investor relations and R

5、egistrar 208Taxation information for shareholders 210Glossary of terms 211Index 212Business reviewThis discusses our financial and non-financial activities,resources,development and performance during 2010 and outlines the factors,including the trends and the principal risks and uncertainties,which

6、are likely to affect future development.Governance and remuneration This discusses our management structures and governance procedures.It also sets out the remuneration policies operated for our Directors and Corporate Executive Team members.Financial statementsThe financial statements provide a sum